Bafna Pharmaceuticals Limited is an India-based company, which is engaged in manufacturing of pharmaceutical formulations. The Company exports its products to the Europe, the United Kingdom, Australia, Sri Lanka, Africa, and Commonwealth countries.

Employees

339

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
26-09-18	₹317.20	+1.99%	6,714
26-09-17	₹311.00	+0.65%	12,918
26-09-16	₹309.00	+0.55%	6,535
26-09-15	₹307.30	+1.94%	12,177
26-09-11	₹301.45	-2.00%	11,743

End-of-day quote NSE India S.E.

More quotes

End-of-day quote NSE India S.E. 2026-09-18			5-day change	1st Jan Change
317.20 ^INR	+1.99%		+5.22%	+110.46%

08-11	Bafna Pharmaceuticals Limited Reports Earnings Results for the First Quarter Ended June 30, 2026	CI
06-22	Bafna Pharmaceuticals Limited Announces Board and Committee Changes	CI

Market Cap	7.5B 78.2M 68.19M 64.39M 58.47M 110M 110M 771M 298M 3.82B 294M 287M 12.28B	P/E 2025	42.6x	P/E 2026	23.3x
Enterprise Value	7.86B 81.89M 71.41M 67.43M 61.23M 115M 115M 808M 312M 4B 308M 301M 12.85B	EV / Sales 2025	1.38x	EV / Sales 2026	1.95x
Free-Float	10.3%	Yield 2025 *	-	Yield 2026	-

Markets		Quality
NSE India S.E.	BAFNAPH	End-of-day quote
Bombay S.E.	BAFNAPH	Delayed

08-11	Bafna Pharmaceuticals Limited Reports Earnings Results for the First Quarter Ended June 30, 2026	CI
06-22	Bafna Pharmaceuticals Limited Announces Board and Committee Changes	CI
05-29	Bafna Pharmaceuticals Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2026	CI
02-11	Bafna Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2025	CI
25-09-19	Bafna Pharmaceuticals Limited Appoints Navin Kumar as Non-Executive, Independent Director	CI
25-08-12	Bafna Pharmaceuticals Limited Reports Earnings Results for the First Quarter Ended June 30, 2025	CI
25-08-12	Bafna Pharmaceuticals Limited Approves Reconstitution of Nomination & Remuneration Committee, Effective August 12, 2025	CI
25-06-24	Bafna Pharmaceuticals Limited Announces Board and Committee Changes, Effective from June 24, 2025	CI
25-05-26	Bafna Pharmaceuticals Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2025	CI
25-04-01	Bafna Pharmaceuticals Limited Announces Resignation of Krishna Yeachuri as Independent Director and Cessation as Chairman of Nomination & Remuneration Committee, Effective March 31, 2025	CI
25-02-06	Bafna Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2024	CI
24-11-11	Bafna Pharmaceuticals Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2024	CI
24-08-13	Bafna Pharmaceuticals Limited Reports Earnings Results for the First Quarter Ended June 30, 2024	CI

Bafna Pharmaceuticals Limited Stock

Stocks

BAFNAPH

INE878I01022

Pharmaceuticals

Valuation: Bafna Pharmaceuticals Limited

Chart: Bafna Pharmaceuticals Limited

Latest news: Bafna Pharmaceuticals Limited

Quotes and Performance

Price Extremes

Managers and Directors: Bafna Pharmaceuticals Limited

Generic Pharmaceuticals

Financials

Company Profile

Quotes

1 day	+1.99%
1 week	+5.22%
Current month	+4.26%
1 month	+28.16%
3 months	+105.49%
6 months	+176.38%
Current year	+110.46%

1 week	301.55	317.2
1 month	232.95	318.5
Current year	94.77	318.5
1 year	94.77	318.5
3 years	69	318.5
5 years	69	318.5
10 years	4.4	318.5

Manager	Title	Age	Since
Bansilal Mahaveer C. Bafna CEO	Chief Executive Officer	64	1980-12-31
Melagiri Sridhar DFI	Director of Finance/CFO	-	-
A. Mohanachandran CMP	Compliance Officer	-	2024-05-28

Director	Title	Age	Since
Hemalatha Shanmugam BRD	Director/Board Member	51	2020-09-09
Akilapriya C. Raju BRD	Director/Board Member	-	2020-09-09
Chitra Ravichandran CHM	Chairman	-	-

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
BAFNA PHARMACEUTICALS LIMITED	+1.99%	+5.22%	+141.02%	+260.66%	78.2M
SUN PHARMACEUTICAL INDUSTRIES LTD.	-1.61%	-0.15%	+11.45%	+60.09%	45.94B
OTSUKA HOLDINGS CO., LTD.	-1.02%	-1.90%	+35.99%	+100.50%	37.22B
ZYDUS LIFESCIENCES LIMITED	+2.19%	+3.65%	+10.70%	+80.29%	12.06B
CIPLA LIMITED	+1.32%	+2.09%	-11.64%	+12.41%	11.74B
KRKA, D. D.	-0.95%	0.00%	+18.72%	+150.00%	9.03B
GEDEON RICHTER	+0.39%	+2.39%	+29.99%	+38.63%	7.36B
ONO PHARMACEUTICAL CO., LTD.	-0.06%	+2.97%	+38.90%	-18.67%	7.15B
GLENMARK PHARMACEUTICALS LIMITED	+1.30%	+1.17%	+16.08%	+187.41%	7.2B
SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD.	+0.70%	+1.10%	-44.22%	+5.78%	5.03B
Average	+0.42%	+1.50%	+24.70%	+87.71%	14.28B
Weighted average by Cap.	-0.44%	+0.23%	+17.02%	+73.66%

	2025	2026
Net sales	1.46B 15.2M 13.25M 12.52M 11.37M 21.29M 21.38M 150M 57.85M 742M 57.1M 55.83M 2.39B	1.51B 15.7M 13.69M 12.92M 11.74M 21.99M 22.08M 155M 59.74M 766M 58.96M 57.66M 2.46B
Net income	41.52M 433K 377K 356K 324K 606K 609K 4.27M 1.65M 21.11M 1.63M 1.59M 67.93M	111M 1.16M 1.01M 952K 865K 1.62M 1.63M 11.41M 4.4M 56.43M 4.35M 4.25M 182M
Net Debt	248M 2.58M 2.25M 2.13M 1.93M 3.62M 3.63M 25.46M 9.82M 126M 9.7M 9.48M 405M	354M 3.69M 3.22M 3.04M 2.76M 5.17M 5.19M 36.4M 14.04M 180M 13.86M 13.55M 579M